N
NYMX

Natixis’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Natixis’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,600
Closed -$57K – 916
2016
Q3 		$57K Hold
17,600
– – ﹤0.01% 512
2016
Q2 		$59K Buy
+17,600
New +$43.2K ﹤0.01% 391

Other funds holding NYMX

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Natixis's NYMX Position: Q4 2016 in Review

Natixis sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2016, closing a stake of 17,600 shares — an estimated $57K sold.

Natixis first reported a position in NYMX in Q2 2016 and held it in 2 quarters. The position peaked at $59K in Q2 2016. 29 funds tracked by Wall St. Rank hold NYMX as of Q4 2016.

  • Natixis reported no remaining Nymox Pharmaceutical Corp position as of Q4 2016 after selling out during the quarter.
  • Natixis sold 17,600 Nymox Pharmaceutical Corp shares in Q4 2016, an estimated $57K.
  • Natixis first reported a position in Nymox Pharmaceutical Corp in Q2 2016 and held it in 2 quarters.
  • Natixis's Nymox Pharmaceutical Corp position peaked at $59K in Q2 2016.
  • 29 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2016.

Based on Natixis's 13F filing for Q4 2016, filed 14 Feb 2017.